Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Johan Harmenberg, MD
Oncopeptides AB, Stockholm, Sweden
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Vejle Hospital
Vejle, Denmark
- Turin Hospital Myeloma Unit
Turin, Italy
- Erasmus University Medical Center
Rotterdam, Netherlands
- Sahlgrenska Hospital
Gothenburg, Sweden
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Karmanos Cancer Center
Detroit, Michigan, United States
- Universtity of North Carolina
Chapel Hill, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2013
- Primary completion
- 31 Dec 2017
- Completion
- 31 Mar 2020
- Last update posted
- 23 Oct 2020
- Registered enrollment
- 75
- Registry id
- NCT01897714
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.